Residency · Residency · Respirology

Neuromuscular Respiratory Disease

Overview

Anatomy of Respiratory Neuromuscular Function

The ventilatory pump depends on an integrated chain of neural and muscular structures: brainstem respiratory centers generate the ventilatory drive, which travels via the spinal cord (C3-C5 for diaphragmatic innervation, thoracic segments for intercostal muscles) through peripheral nerves (phrenic and intercostal) across neuromuscular junctions to the respiratory muscles, of which the diaphragm is the most critical, supplemented by the intercostals, abdominals, and accessory muscles. Dysfunction at any level of this pathway can lead to respiratory failure, which is the leading cause of death in many neuromuscular diseases.

Classification by Site of Lesion

Neuromuscular respiratory diseases are classified by the anatomic site of the lesion. Motor neuron diseases include amyotrophic lateral sclerosis (ALS/MND), spinal muscular atrophy (SMA), and post-polio syndrome. Peripheral nerve disorders encompass Guillain-Barre syndrome (GBS), critical illness polyneuropathy, and bilateral phrenic nerve palsy. Neuromuscular junction disorders include myasthenia gravis, Lambert-Eaton syndrome, botulism, and organophosphate poisoning. Myopathies include Duchenne and Becker muscular dystrophy, myotonic dystrophy, inflammatory myopathies, acid maltase deficiency (Pompe disease), and critical illness myopathy.

Respiratory Assessment in NMD

Symptoms of Respiratory Muscle Weakness

The symptoms of respiratory muscle weakness reflect the progressive inability to maintain adequate ventilation. Orthopnea is a cardinal symptom of diaphragmatic weakness, as the supine position eliminates gravity-assisted diaphragmatic descent. Morning headaches, poor sleep quality, and daytime somnolence result from nocturnal hypoventilation. Weak cough leads to recurrent lower respiratory tract infections. Dyspnea progresses from exertional to rest. Difficulty eating or speaking without pausing to breathe indicates advanced ventilatory compromise.

Key Pulmonary Function Measurements

FVC measured in both upright and supine positions is the most important and practical metric for assessing respiratory muscle function. A supine FVC drop exceeding 20% (or 25% by some criteria) from the sitting value indicates significant diaphragmatic weakness. An FVC below 50% predicted signifies significant respiratory muscle weakness, while an FVC below 25-30% predicted or below 1 liter indicates high risk of respiratory failure and is a strong indication for NIV. Maximal inspiratory pressure (MIP) less negative than -60 cmH2O is normal, while values less negative than -30 cmH2O indicate severe inspiratory muscle weakness and represent a threshold for NIV initiation in many guidelines. Maximal expiratory pressure (MEP) below +40 cmH2O indicates impaired cough and represents the threshold for initiating cough augmentation strategies. Sniff nasal inspiratory pressure (SNIP) serves as an alternative to MIP that may be easier to perform, with values below 40 cmH2O in men or 30 cmH2O in women suggesting weakness. Peak cough flow (PCF) below 270 L/min indicates inability to clear secretions effectively, while PCF below 160 L/min during acute illness necessitates mechanical cough assistance.

Nocturnal Monitoring

Overnight oximetry identifies desaturation patterns, with a mean SpO2 below 93% or time spent with SpO2 below 90% exceeding 5% of the night being clinically significant. Transcutaneous CO2 monitoring (TcCO2) or end-tidal CO2 measurement detects rising CO2 during sleep indicating hypoventilation. PSG with CO2 monitoring is the gold standard for identifying the type and severity of sleep-disordered breathing.

<image>A clinical assessment pathway for respiratory evaluation in neuromuscular disease. Start with NMD patient with respiratory symptoms (orthopnea, morning headache, weak cough, recurrent infections). Show assessment battery: FVC sitting AND supine (calculate % drop; > 20% = diaphragmatic weakness), MIP (< -30 cmH2O = severe), MEP (< +40 cmH2O = impaired cough), SNIP, PCF, overnight oximetry/TcCO2, ABG. Decision nodes: FVC > 50% and MIP > -40 = monitor q3-6 months. FVC 30-50% or MIP -30 to -40 or nocturnal desaturation = initiate NIV + cough augmentation. FVC < 25% or daytime hypercapnia or FVC decline > 10% per year = urgent NIV initiation, discussion of long-term ventilation options, advance care planning. Show monitoring frequency recommendations at each stage. Include thresholds for cough assist (PCF < 270 L/min) and NIV initiation.</image>

Disease-Specific Considerations

Amyotrophic Lateral Sclerosis (ALS/MND)

ALS is a progressive motor neuron degenerative disease with a median survival of 3-5 years from symptom onset. Respiratory failure is the primary cause of death and may be the presenting feature in bulbar-onset ALS. The AAN Practice Parameter and NICE guidelines recommend initiating NIV when FVC falls below 50% predicted, MIP is less negative than -60 cmH2O, SNIP is below 40 cmH2O, or symptoms of nocturnal hypoventilation are present with abnormal overnight oximetry or TcCO2. NIV in ALS extends survival by a median of 7-13 months as demonstrated by Bourke and colleagues, improves quality of life, provides the greatest benefit in limb-onset ALS, and offers limited survival benefit in severe bulbar dysfunction though quality of life may still improve. FVC should be monitored every 3 months, with the rate of decline being more prognostic than the absolute value, and a decline exceeding 10% per 3 months suggesting rapid progression. Diaphragm pacing, while FDA-approved, was shown in the DiPALS trial to provide no benefit and possible harm, and is not currently recommended. Cough augmentation with mechanical insufflation-exsufflation (MI-E/CoughAssist) should be initiated when PCF falls below 270 L/min, complemented by lung volume recruitment through breath stacking. End-of-life planning, including discussion of invasive ventilation versus palliative care, should occur early, as tracheostomy ventilation can extend survival by years but with significant caregiver burden.

Guillain-Barre Syndrome (GBS)

GBS is an acute inflammatory demyelinating polyradiculoneuropathy presenting with ascending weakness and respiratory failure in 20-30% of cases. Monitoring requires serial FVC measurement every 4-6 hours in the ICU, with the "20/30/40 rule" guiding intubation decisions: FVC below 20 mL/kg, MIP less negative than -30 cmH2O, or MEP below +40 cmH2O should prompt consideration of elective intubation. Additional criteria include FVC decline exceeding 30% from baseline, inability to count to 20 in one breath, and bulbar dysfunction with aspiration risk. The role of NIV is limited in GBS due to the potential for rapid deterioration and aspiration risk, and elective intubation is preferred when respiratory failure is anticipated. Treatment consists of IVIG at 0.4 g/kg/day for 5 days or plasma exchange with 5 sessions over 2 weeks; corticosteroids are not effective. Most patients recover respiratory function, though weeks of ventilatory support with gradual weaning may be required.

Myasthenia Gravis

Myasthenia gravis is an autoimmune neuromuscular junction disease characterized by anti-AChR antibodies in 85% or anti-MuSK antibodies in 5-8% of cases. Myasthenic crisis, defined as respiratory failure requiring ventilatory support, is triggered by infection, surgery, medication changes, or non-adherence. Serial FVC monitoring guides management: FVC below 20 mL/kg or below 1 liter warrants ICU admission, and FVC below 15 mL/kg warrants intubation. Treatment of crisis involves IVIG or plasma exchange, with chronic management including cholinesterase inhibitors (pyridostigmine), immunosuppression (prednisone, azathioprine, mycophenolate), rituximab, and newer agents including eculizumab and ravulizumab (anti-C5 complement inhibitors approved for anti-AChR-positive refractory generalized MG) and efgartigimod (FcRn inhibitor). NIV may temporize but requires close monitoring, with intubation if deterioration occurs. Critical medication precautions apply: aminoglycosides, fluoroquinolones, beta-blockers, magnesium, and neuromuscular blocking agents can all worsen myasthenia gravis.

Duchenne Muscular Dystrophy (DMD)

DMD is an X-linked dystrophinopathy with loss of ambulation by age 10-12 and respiratory decline accelerating after loss of ambulation. Scoliosis surgery stabilizes the spine but does not prevent respiratory decline, and preoperative FVC and cough assessment are critical. FVC declines at approximately 5-8% per year after age 10, and NIV should be initiated when FVC falls below 50% or earlier if symptomatic. Daytime ventilation becomes necessary when FVC falls below 20-25% or daytime hypercapnia develops. Cough augmentation with MI-E devices is essential, and family training should begin early. Cardiac involvement with cardiomyopathy is universal by age 18, requiring prophylactic ACE inhibitor/ARB and beta-blocker therapy. Life expectancy has improved to the third and fourth decades with proactive respiratory management combining NIV and cough assistance.

Myotonic Dystrophy (DM1)

Myotonic dystrophy type 1 is an autosomal dominant CTG repeat expansion disorder and the most common adult muscular dystrophy. Respiratory involvement includes central hypoventilation with excessive daytime sleepiness that is often disproportionate to the AHI (reflecting a central hypersomnia component), respiratory muscle weakness, and pharyngeal weakness with aspiration risk. Sleep-disordered breathing involves both central and obstructive apneas. Patients demonstrate extreme sensitivity to sedatives and opioids, with substantial risk of postoperative respiratory failure and a contraindication to depolarizing neuromuscular blockers (succinylcholine causes prolonged contracture). NIV is used for nocturnal hypoventilation, and modafinil may address excessive daytime sleepiness when it is not attributable to sleep-disordered breathing.

Non-Invasive Ventilation in NMD

Indications

NIV is indicated for symptomatic nocturnal hypoventilation (morning headaches, disrupted sleep, daytime somnolence), FVC below 50% predicted (or below 80% if rapidly declining), MIP less negative than -60 cmH2O or SNIP below 40 cmH2O, nocturnal SpO2 below 88% for more than 5 minutes or TcCO2 above 55 mmHg during sleep, and daytime hypercapnia with PaCO2 of 45 mmHg or greater.

Setup and Monitoring

Bilevel PAP in spontaneous/timed (ST) mode with a backup rate is the standard configuration, with typical initial settings of IPAP 12-20 cmH2O, EPAP 4-6 cmH2O, and backup rate 12-14. Nasal masks are preferred when tolerated for their lower claustrophobic effect and preservation of coughing and communication ability, with oronasal masks used when significant mouth leak occurs. Volume-targeted modes such as AVAPS and iVAPS may improve adherence and ventilation consistency. Mouthpiece ventilation using a sip-and-puff technique provides daytime support for advanced NMD and extends tracheostomy-free survival.

Cough Augmentation Strategies

Lung volume recruitment through breath stacking with a manual resuscitation bag or NIV increases lung volume before the cough effort. Mechanical insufflation-exsufflation (MI-E/CoughAssist) delivers positive pressure during insufflation followed by rapid negative pressure during exsufflation, with typical settings of +40/-40 cmH2O, a 2-second inhale, 2-second exhale, and 1-second pause, applied in sets of 3-5 cycles. Manually assisted cough using an abdominal thrust timed with the patient's expiratory effort augments expiratory force. Cough augmentation should be initiated when PCF falls below 270 L/min and intensified during respiratory infections when PCF drops further.

<image>A comprehensive diagram of cough augmentation techniques for neuromuscular disease. Show three panels: (1) Lung volume recruitment - patient using a manual resuscitation bag with one-way valve to stack breaths, expanding the lungs to maximum capacity before coughing; include a volume-time graph showing stepwise volume increase. (2) Mechanical insufflation-exsufflation (MI-E) - show the device connected to a face mask, with pressure waveform diagram showing insufflation (+40 cmH2O) phase followed by rapid exsufflation (-40 cmH2O) phase; label the timing cycle. (3) Manually assisted cough - show proper hand positioning for abdominal thrust timed with patient's expiratory effort. Include a decision algorithm at bottom: PCF thresholds (> 270 = monitor, 160-270 = train techniques and provide MI-E for illness, < 160 = routine MI-E use, < 100 = critical - intensive management).</image>

Diaphragmatic Dysfunction

Bilateral Diaphragm Paralysis

Bilateral diaphragm paralysis may result from neuralgic amyotrophy (Parsonage-Turner syndrome), cardiac surgery (phrenic nerve injury), cervical spine surgery or injury, ALS, or GBS. Orthopnea is the cardinal symptom, with supine FVC dropping more than 50%. Diagnosis is established through the SNIFF test on fluoroscopy (demonstrating paradoxical upward motion of the diaphragm during a sniff maneuver), phrenic nerve conduction studies, and diaphragm ultrasound (M-mode showing excursion below 10 mm and thickening ratio below 1.2). Treatment involves nocturnal NIV and addressing the underlying cause when possible.

Unilateral Diaphragm Paralysis

Unilateral diaphragm paralysis is often asymptomatic but may cause exertional dyspnea, with FVC drop below 20% from upright to supine. The most common cause is idiopathic (viral neuritis), with other causes including cardiac surgery and malignancy with phrenic nerve invasion. Management involves observation, with diaphragm plication considered for symptomatic patients with stable paralysis for more than 6 months without recovery.

Key Clinical Pearls

• Supine FVC drop > 20% from sitting FVC is the most practical bedside test for diaphragmatic weakness; always measure FVC in both positions in suspected NMD
• In GBS, the "20/30/40 rule" (FVC < 20 mL/kg, MIP < -30, MEP < +40) guides intubation decisions; do NOT wait for overt respiratory failure; elective intubation is safer than emergent
• NIV extends survival in ALS by 7-13 months and improves quality of life; it should be offered to all ALS patients meeting criteria, though benefit is reduced in severe bulbar dysfunction
• Peak cough flow < 270 L/min indicates ineffective cough and requires cough augmentation (MI-E/breath stacking); during intercurrent illness, PCF drops further and intensive cough management prevents pneumonia
• Myotonic dystrophy patients have extreme sensitivity to sedatives and anesthetics; respiratory failure can occur with standard doses, making perioperative management high-risk

References

1. Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5(2):140-147.
2. Benditt JO. Respiratory complications of amyotrophic lateral sclerosis. Semin Respir Crit Care Med. 2019;40(4):534-543.
3. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). Neurology. 2009;73(15):1227-1233.
4. Chatwin M, Toussaint M, Goncalves MR, et al. Airway clearance techniques in neuromuscular disease: a state of the art review. Respir Med. 2018;136:98-110.
5. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347-361.

Read this lecture as Markdown